BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Large Increase in Short Interest

BioHarvest Sciences Inc. (NASDAQ:BHST) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 64,005 shares, an increase of 92.8% from the December 15th total of 33,198 shares. Based on an average daily volume of 54,486 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.4% of the company’s stock are short sold. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 54,486 shares, the days-to-cover ratio is presently 1.2 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of BioHarvest Sciences to a “hold” rating in a research note on Saturday, October 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, BioHarvest Sciences has a consensus rating of “Hold” and a consensus price target of $14.50.

BioHarvest Sciences Stock Performance

NASDAQ BHST opened at $5.18 on Thursday. The company has a market capitalization of $85.06 million, a PE ratio of -7.62 and a beta of 1.12. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.02 and a current ratio of 1.35. BioHarvest Sciences has a 52-week low of $4.72 and a 52-week high of $12.80. The company has a 50-day simple moving average of $5.99 and a 200 day simple moving average of $7.86.

BioHarvest Sciences (NASDAQ:BHST) last released its earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. The firm had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $9.11 million. On average, research analysts predict that BioHarvest Sciences will post -0.8 EPS for the current year.

Institutional Trading of BioHarvest Sciences

A hedge fund recently raised its stake in BioHarvest Sciences stock. True North Advisors LLC raised its position in BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 168,013 shares of the company’s stock after buying an additional 146,365 shares during the quarter. True North Advisors LLC owned about 1.02% of BioHarvest Sciences worth $1,581,000 at the end of the most recent reporting period.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.